Cite
Nucleoside/nucleotide reverse transcriptase inhibitors attenuate angiogenesis and lymphangiogenesis by impairing receptor tyrosine kinases signalling in endothelial cells.
MLA
Song, Lin, et al. “Nucleoside/Nucleotide Reverse Transcriptase Inhibitors Attenuate Angiogenesis and Lymphangiogenesis by Impairing Receptor Tyrosine Kinases Signalling in Endothelial Cells.” British Journal of Pharmacology, vol. 175, no. 8, Apr. 2018, pp. 1241–59. EBSCOhost, https://doi.org/10.1111/bph.14036.
APA
Song, L., Ding, S., Ge, Z., Zhu, X., Qiu, C., Wang, Y., Lai, E., Yang, W., Sun, Y., Chow, S. A., & Yu, L. (2018). Nucleoside/nucleotide reverse transcriptase inhibitors attenuate angiogenesis and lymphangiogenesis by impairing receptor tyrosine kinases signalling in endothelial cells. British Journal of Pharmacology, 175(8), 1241–1259. https://doi.org/10.1111/bph.14036
Chicago
Song, Lin, Sha Ding, Zhen Ge, Xiaolong Zhu, Cong Qiu, Yuewen Wang, Enyin Lai, et al. 2018. “Nucleoside/Nucleotide Reverse Transcriptase Inhibitors Attenuate Angiogenesis and Lymphangiogenesis by Impairing Receptor Tyrosine Kinases Signalling in Endothelial Cells.” British Journal of Pharmacology 175 (8): 1241–59. doi:10.1111/bph.14036.